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ABSTRACT 
Purpose: The contribution of serial prostate specific antigen (PSA) determinations was studied 
to obtain better understanding of the natural history of clinically confined prostate carcinoma. 
Materials and Methods: Serial PSA determinations in 29 patients with untreated confined 
prostate carcinoma were correlated to the clinical course for a mean of 39 months. 
Results: Disease progressed locally in 13 patients after a mean of 31 months. Metastatic 
progression was not observed. Neither grade, stage, PSA changes nor initial PSA showed 
significant differences with respect to interval of progression between patients with and without 
progression. 
Conclusions: PSA does not parallel clinical progression in patients selected for watchful 
waiting. 
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Our study was done to contribute to a better understand- 
ing of the natural history of clinically confined prostate car- 
cinoma and to determine the contribution of serial prostate 
specific antigen (PSA) measurements. For this reason PSA 
determinations were correlated with the clinical course in 29 
patients in whom a policy of watchful waiting was applied. In 
several studies increasing PSA levels predicted later clinical 
progression.'-4 The interval between both events depends on 
tumor stage at  diagnosis or treatment. Regarding the corre- 
lation of PSA increase and progression in stages T1 and T2 
tumors with time, little information is available in the liter- 
ature. With regard to the uncertainties of identifying local 
progression it may well be possible that an increase in PSA 
level is a more accurate indicator of progressive disease in 
these patients. 
PATIENTS AND METHODS 
We evaluated retrospectively 29 patients with histologi- 
cally confirmed adenocarcinoma of the prostate from the time 
of diagnosis until the time of first treatment, if any, for 
cancer-related progression. Mean patient age was 74 years 
(range 58 to 85), and mean followup was 39 months (range 11 
to 73). Stage was assessed clinically by digital rectal exami- 
nation according to the 1992 TNM classification.6 In 15 pa- 
tients with stage Tla disease previously unsuspected carci- 
noma was found in the transurethral resection specimens. 
Grade was determined according to the Anderson classifica- 
tion.6 Metastatic disease was excluded by a normal chest 
x-ray and a normal bone scan. The decision not to treat at 
diagnosis was made by the urologist in discussion with the 
patient and his family, with respect to patient age, general 
health, clinical stage and patient preference. All patients 
were considered to have a probable survival of at  least 1 year. 
Followup. Patients usually were followed clinically twice 
yearly (mean 2.7 annual visits, range 1.4 to 4.3). Physical 
examination was done, including digital rectal examination, 
and serum PSA and alkaline phosphatase levels were assessed 
at each visit h m  the time of diagnosis. #en no PSA value was 
available at diagnosis (baseline value) but PSA was obtained 1 
or more months afterwards, this value was extrapolated by 
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linear regression from the logarithmically transformed PSA 
values versus time during the first 2 years after diagnosis for 
individual patients. This method was evaluated by applying the 
procedure to 10 patients in whom a baseline value of PSA was 
available. In this group the correlation between the extrapo- 
lated value obtained and the actual value was good (r = 0.981, 
indicating its validity. Thus, the values obtained when no baee- 
line value was available were used in all M e r  calculations 
when a baseline value was needed (except for 1 patient in whom 
PSA followup began 2 years aRer diagnosis). Bone scan and 
chest x-ray were repeated regularly and when clinically indi- 
cated. In 14 patients serial transrectal ultrasonic volumeby of 
the prostate was performed. 
Staging and progression. Of 29 patients whose disease was 
classified according to the 1992 TNM system 15 had stage 
Tla, 13 stage T2 and 1 stage T3 tumor. There were 11 grade 
1,15 grade 2 and 1 grade 3 cancers (grade was unknown in 
2 patients). Mean patient age was 74 years (range 58 to 85). 
The distribution of age and grade with the T categories is 
summarized in the table. 
Local and metastatic progression was evaluated. Subjec- 
tive progression, like obstructive micturition or pain, was 
considered for treatment decisions. Local subjective progres- 
sion occurred in most patients at  the same time as or later 
than local objective progression. Local objective progression 
was defined as an increase in T category, when prostate size 
increased on digital rectal examination by 25% or more of the 
products of the 2 largest perpendicular parameters, or by an 
ultrasound measured volume of more than 40%. Objective 
metastatic progression was diagnosed by the appearance of 
new lesions on a bone scan. Bone scans were performed for 
initial staging and afterwards when indicated only. For the 
purpose of defining clinical progression, an increase in serum 
Distribution of patient age and gmdo with T categories 
Grade (No. pta.) 
Category (yrs.) 1 2 3 
No.%. T 
Tla 15 74 7 7 1 
12 11 77 3 6 -  
T3 3 72 1 2 -  
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markers alone was not considered relevant. In case of pro- 
gression the patients remained in the study up to the time of 
initial therapy, which may have been started because of 
subjective or objective local or distant progression. 
During the course of this study only 1 patient died of a 
cause not related to disease (another malignancy). The day- 
to-day coefficient of variation of the Hybritech PSA assay 
related to 3 "stable" standards for 50 days varied between 6.9 
and 18.8%. 
Statistical analysis included Kaplan-Meier curves for anal- 
ysis of interval to progression in patients according to stage 
and grade. The changes in PSA and prostate volume were 
expressed by the slopes of the log-linear c w e s  versus time. 
In 1 patient 1 serial PSA value was extremely low without 
evident reason. This outlier was not included in the calcula- 
tions of PSA slopes. The Mann-Whitney test was used to 
evaluate differences among various groups of patients re- 
garding these slopes. The level of statistical significance was 
set at p = 0.05 (2-tailed). The relationship between progres- 
sion rates and PSA level or its change from the baseline value 
was evaluated using Cox regression allowing for time-depen- 
dent variables.' The relationship between PSA levels and 
simultaneous prostate volume measurements, allowing for 
inter-patient and intra-patient differences, was assessed by 
computer using regression analysis. 
RESULTS 
During followup 13 of 29 patients had local progression 
after a mean of 31 months. Metastatic progression was not 
noted. Of these patients with progression 6 started therapy: 
5 for subjective symptoms at  or within 3 months after pro- 
gression and 1 for objective progression only. Two patients 
with local objective and subjective progression did not begin 
therapy. Disease did not progress in 16 patients (mean fol- 
lowup 40 months). 
Figure 1 shows the Kaplan-Meier curves for interval to 
progression for all patients, and for stage T l  versus stages T2 
to T3 and grade 1 versus grades 2 to 3 cancer. There was no 
statistical difference in interval to progression among the 
different grades or the Werent T categories. The mean num- 
ber of PSA recordings per patient was 8.7. Figure 2 shows the 
scatterplots of PSA with time in linear plotting for patients 
with and without clinical progression. Slopes of PSA regres- 
sion curves comparing progressive and nonprogressive dis- 
ease were not signiscantly Merent. Figure 3 shows a plot of 
the PSA doubling time for the individual patients, separated 
for those with and without progression. Also, a percentage 
PSA increase from a baseline of 20% with time was tested as 
an indicator of progression (fig. 4). At no point on the indi- 
vidual curves was it possible to predict clinical progression. 
The same applied to the cutoff level of a 50% increase in PSA 
with time. 
Longitudinal measurements of ultrasonic prostatic volume 
were made in 14 patients. The mean annual increase in 
)rostatic volume in these patients was 15%. The mean in- 
:rease in volume was not significantly different between 
jatients with and without progression. A volume increase of 
nore than 40%, which would qualify a patient for clinical 
xogression on the basis of transrectal ultrasonography, was 
lot observed. There was a weak, although significant, corre- 
lation between volume and PSA (fig. 5). Changes in both 
parameters within patients, however, were not significantly 
related to each other. 
DISCUSSION 
In our study an attempt was made to identify the rate and 
interval of progression in 29 patients with locally confined 
prostate cancer treated by a policy of watchful waiting. In no 
instance was systemic progression observed during an aver- 
age observation of 31 months. Local progression was identi- 
fiable as an increase in T category or as a palpable increase 
in prostate size in conjunction with subjective progression of 
the tumor.8 A volume increase on transrectal ultrasound of 
40% or more was not ~bserved.~ PSA increase was indepen- 
dently studied and compared with clinical progression. 
Our information presented is likely to be biased by patient 
selection and is certainly not representative of men for whom 
radical prostatectomy would normally be recommended. 
However, the data may be compatible with patient popula- 
tions presented in other surveillance studies, such as those 
summarized in the overview by Chodak et  a1.l0 The selection 
bias is reflected in the high average patient age, large pro- 
portion of grade 1 and stage Tla  tumors, and absence of high 
grade lesions. The median interval to progression for stages 
T1 and T2 to T3 cancer patients was approximately 42 
months for both groups (fig. 11, which is shorter than that 
reported by Lowe and Listrom," and Schrijder in 1993 for 
stage Tla  tumors (approximately 13 years),12 and by Whit- 
more et all3 for stage T2 tumors (approximately 10 years). 
Several methods of analyzing PSA increase have been ap- 
plied. PSA velocity, which represents the absolute annual 
PSA increase, was used by Carter et a1 in a select group of 52 
men to discriminate between prostate carcinoma and benign 
disease." A discriminatory cutoff value of 0.75 ng./ml. per 
year was not confirmed by Brawer et  a1 in a community- 
based population of 701 men.l6 In that study the participants 
underwent further evaluation by digital rectal examination 
when the PSA level increased more than 20% within 1 year. 
Prostate carcinoma was found eventually in 5% of these men. 
Oesterling et  a1 noted an age independent annual increase in 
PSA among several age groups in a community-based cohort 
of 376 men.l6 The mean annual increase in PSA was 5.1 to 
11.4% but it was extremely variable partly due to the fact 
that the followup was 1 year and only 2 PSA measurements 
were obtained. In 1.1% of the cases carcinoma developed, 
with a mean annual PSA increase of 59%. 
In our study increases in PSA with time could not discnm- 
hate between nonprogressive, often incidentally found, lo- 
FIG. 1. Ka Ian Meier curves for interval to progression for all patients (A), separated for stage Tl versus stages T2 to 3 ( B )  and for grade 
1 vemus grates it, 3 (C).  Tick marks along curves denote ends of followup of some patients. 
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FIG. 3. Plot of PSA doubling times for patients with and without 
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FIG. 4. Kaplan-Meier curves for interval to progression for 19 
patients from time of PSA increase of 20% or more without prior 
clinical progression (ID versus 28 atienta during period as long as 
FSA increase was less than 2096 (8. 
calized prostate carcinoma and progressive disease. Also, the 
annual PSA increases during year 1,2 or 3 of the evaluation 
were not markers for progression, which means that al- 
though there was a wide variety in PSA velocity and PSA 
doubling times (fig. 3), these parameters were not useful in 
these cases for this study period. 
Our report confirms the PSA doubling time for organ- 
confined prostate carcinoma found in other studies. In 43 
untreated patients with prostate carcinoma Schmid et a1 
observed that 20 of 28 with organconfined carcinoma had a 
PSA doubling time of more than 4 years." The PSA doubling 
time in cases of higher grades or stages was faster than for 
others. Although 14% of all patients had a stable PSA level it 
was concluded that prostate carcinoma has an exponential 
growth rate. In our study 17 of 29 patients had a H A  dou- 
bling time of more than 4 years. In the study of Cadeddu et 1 .  - 
al the PSA doubling time in 11 patients with confined disease 
versus 5 with progression to metastasis was not statistically 
different.18 Carter et al mentioned that the linear increase in 
PSA level between patients with benign prostatic hyperpla- 
sia and prostatic carcinoma (up to diagnosis) was statistically 
different but from the PSA curves it is obvious that this PSA 
velocity has no prognostic value.14 
A low PSA level has been associated with long-term sur- 
vival in a study by Belville et al of 26 patients with stage A1 
prostate carcinoma.l9 The patients had an age distribution 
similar to that of our study population (median age 72 years). 
All tumors had well differentiated histology. Of the PSA 
levels 96% were less than 3.0 ngJml. Evaluation aRer a 
median followup of 12.5 years showed that in all patients the 
prostate carcinoma remained localized, although 6 (23%) had 
Droeression to a DdDable staee. Of our 14 Datients with 
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FIG. 5. Mean PSA level according to volume. Curved lines denote 
95% confidence interval for mean PSA. Disregardi outlying 2 
observations of 1 patient (lower left corner), r e l a t i o z p  was still 
significant (p <0.05). 
values less than 10 ng./ml. 5 had progression. Only physician 
dependent initiation of therapy was found to be more fre- 
quent in patients with higher PSA values. Transrectal ultra- 
sonic volumetry was not helpful as a parameter for progres- 
sion. 
CONCLUSIONS 
In our study population, and probably in similarly select 
groups of patients, watchful waiting is considered justified. 
The absence of metastatic progression is at variance with 
other findings in the literature.20.21 On the basis of our study 
however, it appears to be safe to follow patients with PSA 
determinations, rectal examination, and the intermittent 
evaluation of related symptoms and signs. It must be realized 
that clinical progression may occur without changes in serum 
PSA. 
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